GAD-铝剂延缓HLA-DR3-DQ2阳性儿童3期1型糖尿病:DiAPREV-IT随机试验长期随访
DiAPREV-IT试验将4-17.99岁携带GADA且至少一种其他胰岛自身抗体的儿童随机分配接受两次20 µg GAD-alum或安慰剂注射,间隔30天,随访5年。长期随访中位12.9年后,总体人群GAD-alum对进展无显著影响(HR 1.017;95%CI 0.523,1.977;p=0.960;n=49),但在HLA-DR3-DQ2阳性参与者中显著延缓进展至3期1型糖尿病(HR 0.315;95%CI 0.120,0.823;p=0.018;n=27),而无该单倍型者进展加快(HR 3.500;95%CI 1.052,11.630;p=0.040;n=22)。
要点
- 总体人群GAD-alum未显著延缓3期1型糖尿病进展。
- HLA-DR3-DQ2阳性者GAD-alum显著延缓进展,中位时间9.0年 vs 3.4年。
- 无HLA-DR3-DQ2者GAD-alum进展加快,提示精准医学设计重要性。
核心结论
- GAD-alum在HLA-DR3-DQ2阳性多胰岛自身抗体儿童中显著延缓进展至3期1型糖尿病。
- 无该单倍型者进展加快,支持基于精准医学的研究设计。
研究设计与样本
- 投资者发起的随机安慰剂对照试验DiAPREV-IT长期随访,4-17.99岁GADA阳性且至少一种其他胰岛自身抗体儿童1:1随机接受两次20 µg GAD-alum(n=25)或安慰剂(n=25),间隔30天,5年随访。
- 随访中位12.9年(范围1.0-13.8年),49例纳入分析,1例因基线OGTT血糖达3期1型糖尿病阈值被排除。
- 随机化按胰岛自身抗体状态分层,所有研究 personnel、参与者和照护者均设盲。
主要发现
- 49例中35例进展至3期1型糖尿病;HLA-DR3-DQ2阳性27例中22例发病。
- 总体人群GAD-alum对进展无显著影响(HR 1.017;95%CI 0.523,1.977;p=0.960;n=49)。
- HLA-DR3-DQ2阳性者GAD-alum显著延缓进展(HR 0.315;95%CI 0.120,0.823;p=0.018;n=27)。
- 无HLA-DR3-DQ2者进展加快(HR 3.500;95%CI 1.052,11.630;p=0.040;n=22)。
- HLA-DR3-DQ2阳性者中位进展时间GAD-alum 9.0年 vs 安慰剂3.4年(p=0.096),发病率比0.419(95%CI 0.176,0.997;p=0.049;n=27)。
临床怎么用
- 对携带HLA-DR3-DQ2且多种胰岛自身抗体的儿童,GAD-alum可能作为延缓3期1型糖尿病进展的个体化治疗选择。
- 无HLA-DR3-DQ2单倍型者使用GAD-alum可能加快进展,需避免在该亚组中使用。
局限性
- 长期随访中3期1型糖尿病诊断来自瑞典国家糖尿病登记或电话访谈,非所有参与者均经统一面对面评估。
- 亚组样本量小(HLA-DR3-DQ2阳性27例,阴性22例),结果需更大样本验证。
- 原始RCT预设分析未达显著治疗效应,本随访分析为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to assess the long-term treatment effects of alum-formulated human recombinant GAD65 (GAD-alum) after completion of the Diabetes Prevention - Immune Tolerance (DiAPREV-IT) trial in 2017. A second aim was to determine whether the HLA-DR3-DQ2 haplotype affected the treatment efficacy in delaying or preventing stage 3 type 1 diabetes. METHODS: In the investigator-initiated RCT DiAPREV-IT (EUdraCT number 2008-007484-16/ClinicalTrials.gov registration no. NCT01122446), children 4-17.99 years old with GADA and at least one additional islet autoantibody were randomised 1:1 to receive two subcutaneous injections of 20 µg GAD-alum (n=25) or placebo (n=25), 30 days apart, with a 5 year follow-up. Randomisation was stratified according to islet autoantibody status (two vs three or more islet autoantibodies), and participants were assigned randomisation numbers sequentially according to a prespecified randomisation list. All study personnel, participants and caregivers were masked to treatment allocation. The RCT did not reach significant treatment effect in delaying or preventing stage 3 type 1 diabetes in the predefined analyses. In this long-term follow-up, diagnosis and the date of onset of stage 3 type 1 diabetes were obtained from the Swedish National Diabetes Registry, or, for unregistered participants, through telephone interviews after informed consent. The time from treatment start to stage 3 type 1 diabetes diagnosis was analysed using Cox proportional hazards regression, with Kaplan-Meier estimates being used to visualise survival curves and estimate median time to stage 3 type 1 diabetes diagnosis. Incidence rates were analysed using Poisson regression. Both analyses were performed in the full population and in the subgroups with and without the HLA-DR3-DQ2 haplotype. RESULTS: After a median 12.9 years follow-up (range 1.0-13.8 years), 35 of 49 participants progressed to stage 3 type 1 diabetes. One of the original 50 participants was excluded from the analysis of the follow-up study due to their glucose values at the baseline OGTT in the original DiAPREV-IT study meeting the threshold for stage 3 type 1 diabetes. Among the 27 participants with the HLA-DR3-DQ2 haplotype, 22 developed the disease. In the overall population, GAD-alum showed no significant effect on progression (HR 1.017; 95% CI 0.523, 1.977; p=0.960; n=49). In HLA-DR3-DQ2-positive participants, GAD-alum significantly delayed time to stage 3 type 1 diabetes (HR 0.315; 95% CI 0.120, 0.823; p=0.018; n=27), while an increased rate of progression was observed in individuals without the HLA-DR3-DQ2 haplotype (HR 3.500; 95% CI 1.052, 11.630; p=0.040; n=22). In HLA-DR3-DQ2-positive participants, Kaplan-Meier estimates showed a median time to stage 3 type 1 diabetes of 9.0 years with GAD-alum compared to 3.4 years with placebo (p=0.096), and the incidence rate ratio was 0.419 (95% CI 0.176, 0.997; p=0.049; n=27). CONCLUSIONS/INTERPRETATION: In the current study, GAD-alum significantly delayed progression to stage 3 type 1 diabetes in HLA-DR3-DQ2-positive children with multiple islet autoantibodies, while the opposite was observed in the subgroup without this haplotype, supporting the importance of precision medicine-based study designs and the potential of GAD-alum as a treatment option to delay progression to clinical onset. Trial registration ClinicalTrials.gov NCT01122446.
引用
- Samuelsson H, Hojjati S, Teixeira P, et al. Delayed time to stage 3 type 1 diabetes after GAD-alum treatment in HLA-DR3-DQ2-positive children: follow-up of the randomised placebo-controlled Diabetes Prevention - Immune Tolerance trial. Diabetologia. 2026. PMID: 42806034. doi:10.1007/s00125-026-06875-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。